Adcc clinical trials

Explore recruiting adcc clinical trials.

Recruiting adcc studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Adcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine

France

Therapeutic use (Phase IV) EU CTIS Study details

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/randomized Phase II, open-label multicenter trial to evaluate the safety, tolerability, and efficacy of mFOLFIRINOX with or without BNT321 as adjuvant therapy following curative resection in patients with pancreatic adenocarcinoma

Denmark, Spain, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Adcc trials by city

Adcc in Toronto Adcc in Vancouver Adcc in Montreal Adcc in Calgary Adcc in Edmonton Adcc in Ottawa Adcc in Winnipeg Adcc in Quebec City Adcc in Hamilton Adcc in Kitchener Adcc in London Adcc in Halifax Adcc in New York Adcc in Los Angeles Adcc in Chicago Adcc in Houston

Adcc clinical trials

Recruiting adcc studies right now

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Also recruiting in Europe

CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA study

Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

A Phase I/randomized Phase II, open-label multicenter trial to evaluate the safety, tolerability, and efficacy of mFOLFIRINOX with or without BNT321 as adjuvant therapy following curative resection in patients with pancreatic adenocarcinoma

Adcc trials by city

Other conditions

Adcc clinical trials

Recruiting adcc studies right now

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Also recruiting in Europe

CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA study

Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

A Phase I/randomized Phase II, open-label multicenter trial to evaluate the safety, tolerability, and efficacy of mFOLFIRINOX with or without BNT321 as adjuvant therapy following curative resection in patients with pancreatic adenocarcinoma

Adcc trials by city

Other conditions

A Phase I/randomized Phase II, open-label multicenter trial to evaluate the safety, tolerability, and efficacy of mFOLFIRINOX with or without BNT321 as adjuvant therapy following curative resection in patients with pancreatic adenocarcinoma